

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

JCWSCS 09 APR 2004

PTO/SB/21 (08-03)

**TRANSMITTAL  
FORM***(to be used for all correspondence after initial filing)*

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/724,551
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Christopher J. Nichols
Total Number of Pages in This Submission	10	Attorney Docket Number	15270J-004764US

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Request for Corrected Filing Receipt (2 pp.) w/attached Pages 1 & 2 of a Marked-Up Copy of the Filing Receipt mailed 4/17/01; PAIR Report dated 3/22/04 (2 pp.); Page 2 of Amendment filed 9/3/04; Page 3 of the Initial ADS dated 9/3/04; and, Page 4 of the Examiner's Amendment mailed 12/4/03.
Remarks: The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual	Townsend and Townsend and Crew LLP Rosemarie L. Celli	Reg. No. 42,397
Signature	<i>Rosemarie L. Celli</i>	
Date	March 22, 2004	


**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, Office of Initial Patent Examination, Fax No. (703) 1-703-308-7751 on March 22, 2004.

Typed or printed name	Rosemarie L. Celli		
Signature	<i>Rosemarie L. Celli</i>	Date	March 22, 2004

I hereby certify that this correspondence is being facsimile transmitted to Mr. Preston Wallace at the United States Patent and Trademark Office, Office of Initial Patent Examination, facsimile number 1-703-308-7751 on March 22, 2004

By:

  
Rosemarie L. Celli

PATENT

Attorney Docket No.: 15270J-004764US

Application No.: 09/724,551  
Applicant: Dale B. Schenk  
Filed: November 28, 2000  
TC/A.U.: 1600/1647  
Examiner: Christopher J. Nichols

Confirmation No.: 7121

Docket No.: 15270J-004764US  
Customer No.: 20350

Office of Initial Patent Examination  
United States Patent and Trademark Office

**REQUEST FOR CORRECTED FILING RECEIPT**

Sir:

The above-identified patent application has been allowed and the Issue Fee has been paid. The Applicant appreciates the assistance of Mr. Preston Wallace in the Office of Initial Patent Examination regarding the applicants' request for the expedited issuance of a Corrected Filing Receipt.

Attached hereto is a marked-up copy of the Filing Receipt mailed by the Patent Office on April 17, 2001.

Under Domestic Priority data as claimed by applicant, please delete: "WHICH IS A CIP OF 09/322,289 05/28/1999". In support of the applicants' request, please see attached copies of: 1) the PAIR report dated March 22, 2004; 2) page 2 of the Applicants' Amendment filed September 3, 2003; and, 3) page 3 of the initial Application Data Sheet dated 09/03/04. Each of these papers correctly show that the priority claim for the above-identified patent application is as a Continuation of 09/580,018 05/26/2000.

Application No. 09/724,551


PATENT

Request for Corrected Filing Receipt dated March 22, 2004

Please also correct the Title by deleting "Prevention and Treatment of Amyloidogenic Diseases" and replace it with "N-Terminal Amyloid-Beta Antibodies." In support of the applicants' request, please see the attached copy of the Examiner's Amendment, page 4, of the Notice of Allowability mailed December 4, 2003.

Applicant believes no fee is required for submission of this request. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the previously noted deposit account.

Respectfully submitted,



Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
RLC  
Attachments (as noted)

60170834 v1



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20221  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/724,551	11/28/2000	1847	0.00	15270J- 004764US	18	68	6

CONFIRMATION NO. 7121

20350

TOWNSEND AND TOWNSEND AND CREW  
TWO EMBARCADERO CENTER  
EIGHTH FLOOR  
SAN FRANCISCO, CA 94111-3834

## FILING RECEIPT



"0000000005978026"

Date Mailed: 04/17/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Dale B. Schenk, Burlingame, CA;  
Frederique Bard, Pacifica, CA;  
Theodore Yednock, Forest Knolls, CA;

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/580,018 05/26/2000

~~WHICH IS A CON OF 09/322,280 05/28/1999~~

## Foreign Applications

If Required, Foreign Filing License Granted 04/17/2001

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

## Title

~~Prevention and treatment of amyloidogenic disease~~ N-Terminal Amyloid-Beta Antibodies

TOWNSEND & TOWNSEND  
& CREW  
RECEIVED  
2001 APR 23 AM 11:28

**Preliminary Class**  
**424**

**Data entry by : SALEEKUL, SIRILUCK**

**Team : OIPE**

**Date: 04/17/2001**






PATENT APPLICATION INFORMATION RETRIEVAL



Other Links



Search results for application number: 09/724,551				
Application Number:	09/724,551	Customer Number:	20350	
Filing or 371(c) Date:	11-28-2000	Status:	Publications -- Issue Fee Paid - Not Matched with File	
Application Type:	Utility	Status Date:	03-03-2004	
Examiner Name:	NICHOLS, CHRISTOPHER J	Location:	ELECTRONIC	
Group Art Unit:	1647	Location Date:	12-31-2003	
Confirmation Number:	7121	Earliest Publication No:	-	
Attorney Docket Number:	15270J-004764US	Earliest Publication Date:	-	
Class/ Sub-Class:	530/300	Patent Number:	-	
First Named Inventor:	Dale Schenk, Burlingame, CA (US)	Issue Date of Patent:	-	
Title Of Invention:	N-TERMINAL AMYLOID-BETA ANTIBODIES			

Selected Search Option

Display References	Search
Image File Wrapper	
File History	
Patent Term Adjustment History	
Publication Review	

Parent Continuity Data		
Description	Parent Number	Parent Filing or 371(c) Date
This application is a Continuation of	09/580,018	05-26-2000
Parent Status		
Pending		
Child Continuity Data		
No Child Continuity Data Found.		

[HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



Application No. 09/724,551  
Amendment dated September 3, 2003  
Reply to Office Action of June 3, 2003

**Amendments to the Specification:**

*Please replace the "cross-reference to related applications" section with the following replacement section.*

~~This application is a continuation in part of USSN 322,289, filed May 28, 1999, which is incorporated by reference in its entirety for all purposes.~~

This application is a continuation of U.S. Application No. 09/580,018, filed May 26, 2000.

*Please replace the paragraph beginning on page 2, line 21 of the specification with the following replacement paragraph.*

~~This application is related to Townsend and Townsend and Crew Attorney Docket 015270-004750PC, filed May 26, 2000, PCT/US98/25386, filed November 30, 1998, USSN 60/067,740, filed December 2, 1997, USSN 60/080,970, filed April 7, 1998, and USSN 09/201,430, filed November 30, 1998, each of which is incorporated by reference in its entirety for all purposes.~~

This application is related to International Application No. PCT/US00/14810 filed May 26, 2000, Publication No. WO 00/72880; U.S. Application No. 322,289, filed May 28 1999; PCT/US98/25386, filed November 30, 1998, Publication No. WO 99/27944; U.S. Application No. 09/201,430, filed November 30, 1998; U.S. Application 60/067,740, filed December 2, 1997; and, U.S. Application No., filed April 7, 1998; each of which is incorporated by reference in its entirety for all purposes.

*Please replace the paragraph beginning on page 7, line 14 of the specification with the following replacement paragraph.*

Fig. 10: Lymphocyte Proliferation Assay on spleen cells from AN1792-treated (Fig. 10A)(upper-panel) or PBS-treated (Fig. 10B)(lower-panel).

**Country of Residence::** US  
**Street of Mailing Address::** 184 Arroyo Road  
**City of Mailing Address::** Forest Knolls  
**State or Province of mailing address::** CA  
**Country of mailing address::** US  
**Postal or Zip Code of mailing address::** 94933

**Correspondence Information**

**Correspondence Customer Number::** 20350

**Representative Information**

**Representative Customer Number::** 20350

**Domestic Priority Information**

<b>Application::</b>	<b>Continuity Type::</b>	<b>Parent Application::</b>	<b>Parent Filing Date::</b>
This Application	Continuation of	09/580,018	05/26/00

**Assignee Information**

**Assignee Name::** Neuralab Limited  
**Street of mailing address::** 102 St. James Court  
**City of mailing address::** Flatts  
**State or Province of mailing address::** Smiths  
**Country of mailing address::** Bermuda  
**Postal or Zip Code of mailing address::** FL 04

Application/Control Number: 09/724,551

Page 4

Art Unit: 1647

**Claim 73 (Previously Added)** The pharmaceutical composition of claim 47, which is a sustained release composition.

**Claim 74 (Previously Added)** The pharmaceutical composition of claim 72, which is a sustained release composition.

5. Authorization for this examiner's amendment was given in a telephone interview with Rosemaire Celli (Reg. No. 42,397) on 14 November 2003.

In the Title:

**N-TERMINAL AMYLOID-BETA ANTIBODIES**

### **REASONS FOR ALLOWANCE**

6. The following is an examiner's statement of reasons for allowance:

7. The references cited herein were found by the Examiner during the art searches while preparing the instant Application for allowance. None of the references teach or fairly suggest a human antibody that is specific for an epitope within residues 1-12 (and subsets within) of A $\beta$ .

8. Claims 69 and 70 were amended to be dependent from claim 47 to correct an error made without deceptive intent made by Applicant in the Amendment filed 3 September 2003.